New FDA-approved treatment for raised seborrheic keratosis.
Ortho Dermatologics announced in August that it resubmitted a new drug application to the FDA for DUOBRIITM1, a lotion for the treatment of plaque psoriasis.
In October, the Food and Drug Administratin is expected to decide on the approval of omadacycline (Paratek Pharmaceuticals) for the treatment of acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia.
In June, Dermira Inc. announced the FDA approval of Qbrexza (glycopyrronium) for primary axillary hyperhidrosis ― excessive underarm sweating.
Combination that extends survival in BRAF-mutant metastatic melanoma gains FDA approval.
The July issue of Dermatology Times highlights some newly approved treatments in dermatology including a new wrinkle filler and new treatment for seborrheic keratosis.
The Food and Drug Administration (FDA) has approved rare pediatric disease designation for diacerein 1 percent ointment (CPP-020, Castle Creek Pharmaceuticals) for the treatment of epidermolysis bullosa (EB).
The subcutaneous formulation of Actemra (tocilizumab, Genentech) has been approved by the Food and Drug Administration (FDA) for the treatment of polyarticular juvenile idiopathic arthritis (PJIA) in patients ages 2 years and older, accor
Belgian pharmaceutical firm UCB has entered the immunodermatology field in the U.S. market.
Is it misuse to use medication for off-label uses? A patient sues after developing facial pain and other symptoms associated with the use of a topical for scabies. Is this physician guilty of practicing medicine outside the standard of care?